| Identification | Back Directory | [Name]
TAXIFOLIN 3-O-RHAMNOSIDE | [CAS]
29838-67-3 | [Synonyms]
Astilbin
Taxifolin 3-rhaMnoside
Taxifolin 3-o-rhamnoside
Dihydroquercetin 3-rhamnoside
Astilbin Taxifolin 3-O-rhaMnoside
Astilbin froM Engelhardtia roxburghiana
Astilbin, 98%, from Smilax glabra Roxb.
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-3,4-dihydro-2H-chroMen-3-yl 6-deoxy-alpha-L-Mannopyranoside
(2R,3R)-3-[(6-Deoxy-alpha-L-mannopyranosyloxy)]-2-(3,4-dihydroxy-phenyl)-2,3-dihydro-5,7-dihydroxy-4H-chromen-4-one
(2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-chroman-4-one
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-chroman-4-one
4H-1-Benzopyran-4-one, 3-[(6-deoxy-α-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one | [EINECS(EC#)]
694-695-3 | [Molecular Formula]
C21H22O11 | [MDL Number]
MFCD01632717 | [MOL File]
29838-67-3.mol | [Molecular Weight]
450.4 |
| Chemical Properties | Back Directory | [Melting point ]
180 °C (decomp) | [Boiling point ]
801.1±65.0 °C(Predicted) | [density ]
1.74 | [storage temp. ]
2-8°C | [solubility ]
H2O: soluble1mg/mL, clear, colorless | [form ]
A crystalline solid | [pka]
7.34±0.60(Predicted) | [color ]
White to off-white | [InChIKey]
ZROGCCBNZBKLEL-MQGABXIONA-N | [SMILES]
O([C@]1([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@H]1C(C2=C(C=C(O)C=C2O[C@@H]1C1C=CC(O)=C(O)C=1)O)=O |&1:1,4,6,8,10,12,22,r| |
| Hazard Information | Back Directory | [Description]
Astilbin is a flavonoid that has been found in S. glabra and has diverse biological activities.1,2,3 It inhibits cisplatin-induced increases in apoptosis and accumulation of reactive oxygen species (ROS) in HEK293 cells when used at a concentration of 200 μM.1 Astilbin (50 mg/kg) increases renal glutathione (GSH) levels and superoxide dismutase (SOD) and catalase activity and reduces serum creatinine and blood urea nitrogen (BUN) levels, renal IL-1β, IL-6, and TNF-α levels, apoptosis in kidney tissue, and kidney injury in a mouse model of cisplatin-induced nephrotoxicity. It reduces loss of dopaminergic neurons in the substantia nigra and increases striatal GSH levels and SOD activity in a mouse model of MPTP-induced Parkinson''s disease when administered at a dose of 50 mg/kg per day.2 Astilbin also reduces descent time in a pole test and increases traction test score in a mouse model of Parkinson''s disease, indicating reduced motor deficits. It reduces cell viability of MDA-MB-231 and MCF-7 cells (IC50s = 167.9 and 191.6 μM, respectively), as well as inhibits migration and increases apoptosis when used at concentrations of 50 and 200 μM.3 Astilbin (20 mg/kg every other day for 14 days) reduces tumor growth in an MCF-7 mouse xenograft model. | [Uses]
Astilbin displays anti-depressant activity involving monoaminergic neurotransmitters an the BDNF signal pathway. Anti-oxidant. | [Definition]
ChEBI: A flavanone glycoside that is (+)-taxifolin substituted by a alpha-L-rhamnosyl moiety at position 3 via a glycosidic linkage. |
|
|